This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.Here is a sample of this item:Corcept Therapeutics Announces Pricing of Private Placement Cash Sufficient to Fund Company Through Corlux NDA Submission 2009-10-13 09:48 ET - News Release MENLO PARK, CA
-- (MARKET WIRE)
-- 10/13/09  
Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the development of drugs for the
treatment of severe metabolic and psychiatric disorders, today announced
that it has entered into a definitive agreement with certain existing
investors, including Longitude Capital Management, Sutter Hill Ventures and
Alta Partners, and new investors including Federated Kaufmann Funds to
raise approximately $18 million in gross proceeds in a private placement
through the sale of shares of its common stock and warrants.
Corcept intends to use the net proceeds from the offering to fund the
completion of enrollment in its Phase 3 trial of CORLUX© for Cushing's
Syndrome and the submission of its Cushing's Syndrome NDA, as well as for
general corporate purposes, including working capital.
The remainder is available to Stockwatch subscribers.
If you would like to give the Stockwatch system a try,
click here for a free 30 day trial subscription. |
Top
Print this Page